Advances in the development of new tuberculosis drugs and treatment regimens

被引：711

作者：

Zumla, Alimuddin ^{[1
]}

Nahid, Payam ^{[2
]}

Cole, Stewart T. ^{[3
]}

机构：

[1] UCL, Div Infect & Immun, Ctr Clin Microbiol, London NW3 2PF, England

[2] Univ Calif San Francisco, Div Pulm & Crit Care, San Francisco Gen Hosp, San Francisco, CA 94110 USA

[3] Ecole Polytech Fed Lausanne, SV GHI UPCOL, Stn 19, Global Hlth Inst, CH-1015 Lausanne, Switzerland

来源：

NATURE REVIEWS DRUG DISCOVERY | 2013年 / 12卷 / 05期

基金：

英国医学研究理事会; 美国国家卫生研究院;

关键词：

EARLY BACTERICIDAL ACTIVITY; KILL MYCOBACTERIUM-TUBERCULOSIS; PULMONARY TUBERCULOSIS; RESISTANT TUBERCULOSIS; ATP SYNTHASE; IN-VITRO; ANTIRETROVIRAL THERAPY; DOSE RIFAMPIN; BENZOTHIAZINONES; MOXIFLOXACIN;

D O I：

10.1038/nrd4001

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Despite the introduction 40 years ago of the inexpensive and effective four-drug (isoniazid, rifampicin, pyrazinamide and ethambutol) treatment regimen, tuberculosis (TB) continues to cause considerable morbidity and mortality worldwide. For the first time since the 1960s, new and novel drugs and regimens for all forms of TB are emerging. Such regimens are likely to utilize both repurposed drugs and new chemical entities, and several of these regimens are now progressing through clinical trials. This article covers current concepts and recent advances in TB drug discovery and development, including an update of ongoing TB treatment trials, newer clinical trial designs, TB biomarkers and adjunct host-directed therapies.

引用

页码：388 / 404

页数：17

共 130 条

[71] Successful Shortening of Tuberculosis Treatment Using Adjuvant Host-Directed Therapy with FDA-Approved Phosphodiesterase Inhibitors in the Mouse Model [J].

Maiga, Mamoudou ;

Agarwal, Nisheeth ;

Ammerman, Nicole C. ;

Gupta, Radhika ;

Guo, Haidan ;

Maiga, Marama C. ;

Lun, Shichun ;

Bishai, William R. .

PLOS ONE, 2012, 7 (02)

[72] Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis [J].

Makarov, Vadim ;

Manina, Giulia ;

Mikusova, Katarina ;

Moellmann, Ute ;

Ryabova, Olga ;

Saint-Joanis, Brigitte ;

Dhar, Neeraj ;

Pasca, Maria Rosalia ;

Buroni, Silvia ;

Lucarelli, Anna Paola ;

Milano, Anna ;

De Rossi, Edda ;

Belanova, Martina ;

Bobovska, Adela ;

Dianiskova, Petronela ;

Kordulakova, Jana ;

Sala, Claudia ;

Fullam, Elizabeth ;

Schneider, Patricia ;

McKinney, John D. ;

Brodin, Priscille ;

Christophe, Thierry ;

Waddell, Simon ;

Butcher, Philip ;

Albrethsen, Jakob ;

Rosenkrands, Ida ;

Brosch, Roland ;

Nandi, Vrinda ;

Bharath, Sowmya ;

Gaonkar, Sheshagiri ;

Shandil, Radha K. ;

Balasubramanian, Venkataraman ;

Balganesh, Tanjore ;

Tyagi, Sandeep ;

Grosset, Jacques ;

Riccardi, Giovanna ;

Cole, Stewart T. .

SCIENCE, 2009, 324 (5928) :801-804

[73] Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis [J].

Manjunatha, UH ;

Boshoff, H ;

Dowd, CS ;

Zhang, L ;

Albert, TJ ;

Norton, JE ;

Daniels, L ;

Dickl, T ;

Pang, SS ;

Barry, CE .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (02) :431-436

[74]

Manjunatha Ujjini, 2009, Commun Integr Biol, V2, P215

[75] Mycobacterium leprae is naturally resistant to PA-824 [J].

Manjunatha, Ujjini H. ;

Lahiri, Ramanuj ;

Randhawa, Baljit ;

Dowd, Cynthia S. ;

Krahenbuhl, James L. ;

Barry, Clifton E., III .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (10) :3350-3354

[76]

Marshall G, 1949, BMJ-BRIT MED J, V1, P382

[77] OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice [J].

Matsumoto, Makoto ;

Hashizume, Hiroyuki ;

Tomishige, Tatsuo ;

Kawasaki, Masanori ;

Tsubouchi, Hidetsugu ;

Sasaki, Hirofumi ;

Shimokawa, Yoshihiko ;

Komatsu, Makoto .

PLOS MEDICINE, 2006, 3 (11) :2131-2144

[78] Tuberculosis Diagnostics and Biomarkers: Needs, Challenges, Recent Advances, and Opportunities [J].

McNerney, Ruth ;

Maeurer, Markus ;

Abubakar, Ibrahim ;

Marais, Ben ;

Mchugh, Timothy D. ;

Ford, Nathan ;

Weyer, Karin ;

Lawn, Steve ;

Grobusch, Martin P. ;

Memish, Ziad ;

Squire, S. Bertel ;

Pantaleo, Giuseppe ;

Chakaya, Jeremiah ;

Casenghi, Martina ;

Migliori, Giovanni-Batista ;

Mwaba, Peter ;

Zijenah, Lynn ;

Hoelscher, Michael ;

Cox, Helen ;

Swaminathan, Soumya ;

Kim, Peter S. ;

Schito, Marco ;

Harari, Alexandre ;

Bates, Matthew ;

Schwank, Samana ;

O'Grady, Justin ;

Pletschette, Michel ;

Ditui, Lucica ;

Atun, Rifat ;

Zumla, Alimuddin .

JOURNAL OF INFECTIOUS DISEASES, 2012, 205 :S147-S158

[79] A pivotal registration phase III, multicenter, randomized tuberculosis controlled trial: design issues and lessons learnt from the Gatifloxacin for TB (OFLOTUB) project [J].

Merle, Corinne S. C. ;

Sismanidis, Charalambos ;

Sow, Oumou Bah ;

Gninafon, Martin ;

Horton, John ;

Lapujade, Olivier ;

Lo, Mame Bocar ;

Mitchinson, Denis A. ;

Perronne, Christian ;

Portaels, Francoise ;

Odhiambo, Joseph ;

Olliaro, Piero ;

Rustomjee, Roxana ;

Lienhardt, Christian ;

Fielding, Katherine .

TRIALS, 2012, 13

[80] Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis [J].

Migliori, Giovanni Battista ;

Sotgiu, Giovanni ;

Gandhi, Neel R. ;

Falzon, Dennis ;

DeRiemer, Kathryn ;

Centis, Rosella ;

Hollm-Delgado, Maria-Graciela ;

Palmero, Domingo ;

Perez-Guzman, Carlos ;

Vargas, Mario H. ;

D'Ambrosio, Lia ;

Spanevello, Antonio ;

Bauer, Melissa ;

Chan, Edward D. ;

Schaaf, H. Simon ;

Keshavjee, Salmaan ;

Holtz, Timothy H. ;

Menzies, Dick .

EUROPEAN RESPIRATORY JOURNAL, 2013, 42 (01) :169-179

← 3 4 5 6 7 8 9 10 11 12 →